Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 799 results for "lymphocyte count"

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone.

Background: A systemic immune-inflammation index (SII) based on neutrophil (N), lymphocyte (L), and platelet (P) counts has shown a prognostic impact in several solid tumors. The aim of this study is to evaluate the prognostic role of SII in ...
 UroToday1 month ago

European Commission Grants Conditional Marketing Approval for AbbVie's VENCLYXTO (venetoclax) Monotherapy for..

- VENCLYXTO (venetoclax) monotherapy is indicated for the treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor ...
 ADVFN India1 day ago Orphan designation: Venetoclax, for the: Treatment of multiple myeloma  European Medicines Agency3 weeks ago
[x]  
LymphomaNewsToday.com

Gazyva Shown to Outperform Rituxan in Phase 3 Trial in Follicular Lymphoma Patients

Patients with follicular lymphoma may soon have a new treatment option, as Genentech recently demonstrated that Gazyva (obinutuzumab) improved survival times without disease progression compared to standard treatment with Rituxan (rituximab). Data ...
 LymphomaNewsToday.com7 minutes ago Genentech's Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared to Rituxan  Benzinga.com4 days ago Genentechs Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer  Newswire Today3 days ago Genentech???s Gazyva Helped People With Previously Untreated Follicular Lymphoma Live Significantly Longer Without Their Disease Worsening Compared To Rituxan  BioSpace3 days ago
[x]  

A rare cause of colonic thickening and lymphadenopathy

Advanced search A 73-year-old retired analytic chemist presented with 4 weeks of epigastric discomfort, weight loss and loose stools. His medical history revealed pancreatic insufficiency on the background of a pancreatic mass, which had resolved ...
 British Journal of the Gut2 days ago

Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting

SAN DIEGO--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today highlighted long-term follow-up data evaluating ADCETRIS (brentuximab vedotin) in T-cell lymphoma at the 58 th American Society of Hematology ...
 Business Wire4 days ago SEATTLE GENETICS : Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting  4 Traders4 days ago Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting  Yahoo! Singapore3 days ago Seattle Genetics and Takeda Complete Enrollment of Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline Mature T-cell Lymphoma  Nasdaq1 month ago
[x]  

Data at ASH 2016 Show Strong, Lasting Efficacy of IMBRUVICA® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

SAN DIEGO AND RARITAN, N.J., Dec. 3, 2016 /PRNewswire/ -- Today, Janssen Research & Development, LLC (Janssen) announced the longest follow-up results to date of patients treated with IMBRUVICA® (ibrutinib) for chronic lymphocytic leukemia/small ...
 Yahoo! Finance5 days ago Janssen R&D Release: Data At American Society of Hematology 2016 Show Strong, Lasting Efficacy Of IMBRUVICA (Ibrutinib) Through Five Years Of Treatment For Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)  BioSpace4 days ago
[x]  

Diffuse Vesicular Eruption

A man in his 70s with a history of chronic lymphocytic leukemia (CLL) and prescribed cyclosporine, 100 mg twice daily, for pure red cell aplasia was admitted for spreading painful blisters on the hands and feet. He had initially developed ...
 Journal of the American Medical Association1 month ago

New Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin's Lymphoma

SAN DIEGO and RARITAN, N.J., Dec. 5, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced results from a Phase 2 study demonstrating a 48% overall response rate (ORR) as assessed by an Independent Review Committee (IRC) ...
 TickerTech.com3 days ago Janssen R&D Release: New Ibrutinib (IMBRUVICA) Phase 2 Data Demonstrate Promise In Relapsed/Refractory Marginal Zone Lymphoma (MZL), A Rare, Incurable Type Of Non-Hodgkin's Lymphoma  BioSpace3 days ago
[x]  

Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting

- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia - NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) Karyopharm Therapeutics Inc.
 Pharmacy Choice4 days ago Karyopharm Presents Updated Phase II SAIL Relapsed/Refractory AML Clinical Data At The American Society of Hematology 2016 Annual Meeting  BioSpace4 days ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less